<DOC>
	<DOCNO>NCT01641250</DOCNO>
	<brief_summary>This multi-center , open-label study evaluate safety , pharmacokinetics , pharmacodynamics efficacy RO5429083 alone combination cytarabine patient acute myelogenous leukemia . In Part A , patient receive multiple escalating dos RO5429083 intravenously . In Part B , patient receive RO5429083 plus 4 cycle cytarabine ( 1000 mg/m2 iv daily 5 consecutive day ) . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5429083 Alone Combination With Cytarabine Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically cytologically confirm , acute myelogenous leukemia ( subtypes except acute promyelotic leukemia ) accord WHO criteria Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 All nonhematological adverse event prior chemotherapy , surgery , radiotherapy must resolve NCICTC AE Grade &lt; 2 , except alopecia Adequate hepatic renal function Patient must willing submit blood bone marrow sample PK PD analyse exploratory biomarkers Patients receive investigational commercial agent therapy administer intention treat malignancy within 14 day first receipt study drug , exception hydroxyurea History allergic reaction attribute component cytarabine and/or formulate product Current evidence CNS leukemia Increased QTc interval ( QTc &gt; 470 m ) , baseline rest bradycardia &lt; 45 beat per minute , baseline rest tachycardia &lt; 100 beat per minute Family history long QT syndrome risk factor torsades de pointes , and/or use concomitant medication prolong QT/QTc interval Uncontrollable intercurrent illness Pregnant breastfeed woman HIVpositive patient receive antiretroviral therapy Patients refuse potentially receive blood product and/or hypersensitivity blood product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>